查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1913432

辅助生殖技术市场机会、成长要素、产业趋势分析及2026年至2035年预测

Assisted Reproductive Technology (ART) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球辅助生殖技术（ART）市场预计到 2025 年将达到 389 亿美元，到 2035 年将达到 798 亿美元，年复合成长率为 7.6%。

辅助生殖技术（ART）市场-IMG1

市场扩张的驱动力在于持续不断的技术创新，这些创新不断改善治疗效果和患者体验。人工智慧辅助胚胎选择、延时成像和胚胎着床前遗传学检测 (PGT) 等技术创新提高了胚胎着床成功率，同时降低了週期失败率，使辅助生殖技术 (ART) 更可靠、更具吸引力。辅助生殖技术 (ART) 是指旨在帮助自然受孕困难的个人和夫妇的医疗程序。它涉及在体外对卵子、精子和胚胎进行操作。社会规范的改变以及对包括单亲家庭和同性伴侣家庭在内的多元化家庭结构的日益包容，正在推动对辅助生殖技术解决方案的需求。公众意识的提高、父母期望的改变以及对替代性生殖方法的接受度不断提高，正在加速市场成长，并为全球的诊所、技术提供者和相关服务提供者创造机会。

市场覆盖范围
开始年份 2025
预测年份 2026-2035
起始值 389亿美元
预测金额 798亿美元
复合年增长率 7.6%

到 2025 年，技术细分市场将达到 312 亿美元，这反映出由于生活方式的改变、环境因素和生育年龄的推迟，人们对先进的生殖健康解决方案有着很高的需求。

预计到 2025 年，生育诊所产业将创造 176 亿美元的收入，主导服务业，其专业设施配备生殖内分泌学家、胚胎学家和生育专家，提供高成功率。

北美辅助生殖技术（ART）市场仍然是最大的区域市场，这得益于其完善的医疗保健基础设施、较高的患者意识、健全的法规结构以及人工智慧胚胎选择、基因筛检和冷冻保存等创新技术的广泛应用。不孕症盛行率的上升以及政府和保险公司为降低经济门槛而采取的倡议，进一步推动了市场对该技术的接受度。

目录

第一章调查方法和范围

第二章执行摘要

第三章业界考察

  • 生态系分析
  • 产业影响因素
    • 司机
      • 人口不孕症日益增多
      • 人口结构变化对辅助生殖技术（ART）接受度的影响
      • 辅助生殖技术的进步
      • 人们对辅助生殖技术的认识不断提高
    • 产业潜在风险与挑战
      • 严格的法规环境
      • 辅助生殖技术高成本
    • 市场机会
      • 个人化和精准生殖医学
  • 成长潜力分析
  • 监管环境
    • 北美洲
    • 欧洲
    • 亚太地区
  • 技术格局
  • 未来市场趋势
  • 波特五力分析
  • PESTEL 分析

第四章 竞争情势

  • 介绍
  • 公司市占率分析
    • 世界
    • 北美洲
    • 欧洲
  • 企业矩阵分析
  • 主要市场公司的竞争分析
  • 竞争定位矩阵
  • 重大进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章 2021-2034年按产品分類的市场估算与预测

  • 培养基
    • 胚胎培养基
    • 冷冻保存介质
    • 精液处理培养基
    • 卵子处理培养基
  • 装置
    • 玻璃化设备
    • 培养箱
    • 精子分析系统
    • 微型操纵器
    • 其他设备
  • 消耗品
    • 导管
    • 针
    • 储存容器
    • 其他消耗品
  • 添加剂

第六章 依治疗方法分類的市场估计与预测，2021-2034年

  • 科技
    • 体外受精（IVF）
      • 体外受精（IVF）结合卵胞浆内单一精子注射（ICSI）
      • 无需ICSI的试管婴儿
    • 人工授精 - 阴道内授精 (AI-IUI)
  • 按类型
    • 新鲜精子捐赠者
    • 新鲜非提供者
    • 冷冻捐赠者
    • 冷冻非捐赠者

7. 依最终用途分類的市场估计与预测，2021-2034 年

  • 医院
  • 不孕不育诊所
  • 冷冻库
  • 其他用途

第八章 2021-2034年各地区市场估算与预测

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国

第九章：公司简介

  • Esco Micro
  • Gynotec
  • Hamilton Thorne
  • Indira IVF Hospital
  • Ivy Fertility
  • Kitazato
  • Laboratoire
  • Liverpool Partners Group
  • Merck
  • MISTRAL FERTILITY CLINICS
  • NidaCon International
  • 库柏公司
  • Thermo Fisher Scientific
  • Vitrolife Group
  • Western Fertility Institute
简介目录
Product Code: 506

The Global Assisted Reproductive Technology (ART) Market was valued at USD 38.9 billion in 2025 and is estimated to grow at a CAGR of 7.6% to reach USD 79.8 billion by 2035.

Assisted Reproductive Technology (ART) Market - IMG1

The market expansion is fueled by continuous technological advancements that enhance treatment effectiveness and patient experience. Innovations such as AI-driven embryo selection, time-lapse imaging, and preimplantation genetic testing (PGT) are improving implantation outcomes while reducing cycle failures, making ART increasingly reliable and appealing. Assisted reproductive technology encompasses medical procedures designed to help individuals or couples conceive when natural conception is challenging, involving the manipulation of eggs, sperm, or embryos outside the body. Changing social norms and greater acceptance of diverse family structures, including single-parent and same-sex families, have broadened the demand for ART solutions. Rising awareness, evolving parental expectations, and growing acceptance of reproductive alternatives have collectively accelerated market growth, creating opportunities for clinics, technology providers, and ancillary service providers globally.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$38.9 Billion
Forecast Value$79.8 Billion
CAGR7.6%

The technology segment reached USD 31.2 billion in 2025, reflecting high demand for advanced reproductive solutions driven by lifestyle changes, environmental factors, and delayed parenthood.

The fertility clinics segment generated USD 17.6 billion in 2025, dominating the service landscape as specialized centers employing reproductive endocrinologists, embryologists, and fertility experts to deliver high success rates.

North America Assisted Reproductive Technology (ART) Market remains the largest regional market, supported by a robust healthcare infrastructure, high patient awareness, strong regulatory frameworks, and widespread adoption of innovative technologies such as AI-based embryo selection, genetic screening, and cryopreservation techniques. Rising infertility prevalence and government or insurance initiatives to reduce financial barriers further strengthen market adoption.

Prominent players in the Global Assisted Reproductive Technology (ART) Market include Hamilton Thorne, Western Fertility Institute, Kitazato, Indira IVF Hospital, Gynotec, Merck, Esco Micro, Ivy Fertility, Laboratoire, Liverpool Partners Group, Thermo Fisher Scientific, The Cooper Companies, Vitrolife Group, NidaCon International, and Mistral Fertility Clinics. Companies in the Global Assisted Reproductive Technology (ART) Market are reinforcing their position through investment in research and development to enhance treatment success rates and patient outcomes. Strategic partnerships with fertility clinics, hospitals, and diagnostic labs help expand service networks and improve accessibility. Adoption of AI, genetic testing, and cryopreservation innovations enables differentiation through advanced and efficient treatment solutions. Firms are also focusing on geographic expansion into high-demand regions and providing patient education programs to build trust and awareness.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Procedures trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of infertility across population base
      • 3.2.1.2 Demographical shift towards acceptance of assisted reproductive technology (ART)
      • 3.2.1.3 Technological advancements in assisted reproductive technology
      • 3.2.1.4 Rising awareness regarding assisted reproductive technology
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory scenario
      • 3.2.2.2 High cost of ART procedures
    • 3.2.3 Market opportunity
      • 3.2.3.1 Personalized and precision reproductive medicine
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Media
    • 5.2.1 Embryo culture media
    • 5.2.2 Cryopreservation media
    • 5.2.3 Semen processing media
    • 5.2.4 Ovum processing media
  • 5.3 Instrument
    • 5.3.1 Vitrification devices
    • 5.3.2 Incubators
    • 5.3.3 Sperm analyzer system
    • 5.3.4 Micromanipulators
    • 5.3.5 Other instruments
  • 5.4 Consumables
    • 5.4.1 Catheters
    • 5.4.2 Needles
    • 5.4.3 Storage containers
    • 5.4.4 Other consumables
  • 5.5 Supplements

Chapter 6 Market Estimates and Forecast, By Procedure, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Technology
    • 6.2.1 In-vitro fertilization (IVF)
      • 6.2.1.1 IVF with intracytoplasmic sperm injection (ICSI)
      • 6.2.1.2 IVF without ICSI
    • 6.2.2 Artificial insemination - intrauterine insemination (AI-IUI)
  • 6.3 Type
    • 6.3.1 Fresh donor
    • 6.3.2 Fresh non donor
    • 6.3.3 Frozen donor
    • 6.3.4 Frozen non donor

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Fertility clinics
  • 7.4 Cryobanks
  • 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Esco Micro
  • 9.2 Gynotec
  • 9.3 Hamilton Thorne
  • 9.4 Indira IVF Hospital
  • 9.5 Ivy Fertility
  • 9.6 Kitazato
  • 9.7 Laboratoire
  • 9.8 Liverpool Partners Group
  • 9.9 Merck
  • 9.10 MISTRAL FERTILITY CLINICS
  • 9.11 NidaCon International
  • 9.12 The Cooper Companies
  • 9.13 Thermo Fisher Scientific
  • 9.14 Vitrolife Group
  • 9.15 Western Fertility Institute